Aditya K Gupta1, Deanne Daigle2, Kelly A Foley2. 1. Department of Medicine, University of Toronto, Toronto, Ont., Canada; Mediprobe Research Inc., London, Ont., Canada. 2. Mediprobe Research Inc., London, Ont., Canada.
Abstract
BACKGROUND: Many onychomycosis treatments have not been directly compared in head-to-head clinical trials. OBJECTIVE: To determine the relative efficacy of onychomycosis treatments using network meta-analysis (NMA). METHODS: We conducted a systematic review and NMA of mycological cure rates. RESULTS: Nineteen trials were included in the network. Terbinafine 250 mg was significantly superior to all treatments except itraconazole 400 mg pulse therapy. The itraconazole 400 mg pulse regimen was significantly superior to all topicals except efinaconazole 10% nail solution. Itraconazole 200 mg was significantly superior to all topical treatments, while fluconazole 150-450 mg, efinaconazole 10% nail solution, tavaborole 5% nail solution, ciclopirox nail lacquer 8%, terbinafine nail solution, and amorolfine 5% nail lacquer were significantly superior to placebo. CONCLUSIONS: Newly developed topicals have improved the odds ratios (ORs) of mycological cure, yet these ORs were not significantly greater than preexisting topical treatments. Further experience with these agents will reveal their clinical significance, and head-to-head trials are warranted.
BACKGROUND: Many onychomycosis treatments have not been directly compared in head-to-head clinical trials. OBJECTIVE: To determine the relative efficacy of onychomycosis treatments using network meta-analysis (NMA). METHODS: We conducted a systematic review and NMA of mycological cure rates. RESULTS: Nineteen trials were included in the network. Terbinafine 250 mg was significantly superior to all treatments except itraconazole 400 mg pulse therapy. The itraconazole 400 mg pulse regimen was significantly superior to all topicals except efinaconazole 10% nail solution. Itraconazole 200 mg was significantly superior to all topical treatments, while fluconazole 150-450 mg, efinaconazole 10% nail solution, tavaborole 5% nail solution, ciclopirox nail lacquer 8%, terbinafine nail solution, and amorolfine 5% nail lacquer were significantly superior to placebo. CONCLUSIONS: Newly developed topicals have improved the odds ratios (ORs) of mycological cure, yet these ORs were not significantly greater than preexisting topical treatments. Further experience with these agents will reveal their clinical significance, and head-to-head trials are warranted.
Authors: Aditya K Gupta; Jennifer E Ryder; Robyn Bluhm; Andrew Johnson; Richard C Summerbell Journal: J Cutan Med Surg Date: 2003-07-28 Impact factor: 2.092
Authors: Boni E Elewski; Phoebe Rich; Richard Pollak; David M Pariser; Shinichi Watanabe; Hisato Senda; Chikara Ieda; Kathleen Smith; Radhakrishnan Pillai; Tage Ramakrishna; Jason T Olin Journal: J Am Acad Dermatol Date: 2012-11-20 Impact factor: 11.527
Authors: R K Scher; D Breneman; P Rich; R C Savin; D S Feingold; N Konnikov; J L Shupack; S Pinnell; N Levine; N J Lowe; R Aly; R B Odom; D L Greer; M R Morman; A D Bucko; E H Tschen; B E Elewski; E B Smith Journal: J Am Acad Dermatol Date: 1998-06 Impact factor: 11.527
Authors: Julia K Christenson; Gregory M Peterson; Mark Naunton; Mary Bushell; Sam Kosari; Kavya E Baby; Jackson Thomas Journal: J Fungi (Basel) Date: 2018-07-24